DLBCL Review Paper Published in The Oncologist

Dr Matthew Matasar is a board-certified medical oncologist/hematologist, who received his undergraduate and medical degrees from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a Master’s in biostatistics, while serving as Chief Resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT services. Dr Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodgkin lymphoma. As the Section Head for Aggressive B-cell Lymphomas, his research is focused on improving outcomes in relapsed but curable patients using novel therapies. He is the Medical Director at MSK Bergen, directing a team of expert oncologists in the delivery of cutting-edge care across cancer service lines to patients at the free-standing outpatient center in Montvale, New Jersey.

Dr Massimo Magagnoli is a haematologist and Associate Director at the Department of Hematology and Clinical Oncology at the Humanitas Cancer Center in Milan. He graduated in medicine from the University of Bologna, where he attended the "Seragnoli" hematology institute, first as a medical student and later as a doctor in specialization. At this institute he specialized in hematology with laude. Since 1999 he works at Humanitas Cancer Center. Dott Magagnoli specializes in the management of non-Hodgkin's lymphomas and chronic lymphatic leukemia. Particular interest is in the study and research of new drugs for lymphoma and chronic lymphatic leukemia. From 1999, he followed and participated in more than 40 Phase I, II and III clinical trials in hematologic malignancies.  Last GCP training (ICH E6 (R2) GCP) on November 2017. Dr Magagnoli other interests in the management of older patients with haematological tumors, and tools to improve the care of this patient population. Massimo is co-author of about 80 peer-reviewed papers

Alexey V. Danilov, MD, PhD, is a Professor of Medicine at the City of Hope National Medical Center, in Los Angeles, CA. He earned his medical degree and PhD at Yaroslavl State Medical Academy in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, Massachusetts. Dr Danilov runs an independently funded clinical/translational program in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) that bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics. He spearheads a translational and early-phase therapeutics effort in B-cell malignancies at the Knight Cancer Institute. In the laboratory, he focuses on targeting stromal-mediated pro-survival signaling in lymphoid malignancies. He has characterized promising therapeutic agents with regard to their mechanism of action and resistance, ushering them into early-phase clinical trials in CLL and NHL. He seeks to translate his findings to clinical care by developing protocols that advance current treatment paradigms. His work has received support from the Leukemia & Lymphoma Society, Lymphoma Research Foundation, the National Cancer Institute, and the Southwest Oncology Group, among other funding organizations. He has been published in numerous peer-reviewed journals including Clinical Cancer Research, Cancer Research, Haematologica, Molecular Cancer Therapeutics, Journal of Immunology and others. Among numerous speaking engagements, Dr Danilov has chaired sessions at the American Society of Hematology Annual Meetings, and has given visiting professor lectures in London and New York. He is a member of the American Society of Hematology and the European Hematology Association. Dr Danilov is a Leukemia & Lymphoma Society Scholar in Clinical Research and a Lymphoma Research Foundation Clinical Investigator.